BRKRP · Bruker Corp
Price & Indicators
Up next
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders illustrative — not investment adviceIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP CER currency revenue non-GAAP | $831.5M | Three Months Ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP GAAP revenue 838.5M
-7M Effect of changes in foreign currency translation rates
= Non-GAAP CER currency revenue 831.5M
|
|||
| Non-GAAP Organic Revenue non-GAAP | $820.1M | Three Months Ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Non-GAAP CER currency revenue 831.5M
-11.4M Acquisitions
= Non-GAAP Organic revenue 820.1M
|
|||
| BSI bookings organic year-over-year growth non-GAAP | 10% | Q2-26 | — |
| Non-GAAP CER currency revenue year-on-year growth rate non-GAAP | 1.2% | Six Months Ended June 30, 2026 | — |
| Non-GAAP free cash flow non-GAAP | -$59.2M | Six Months Ended June 30, 2026 | — |
| Non-GAAP Operating (Loss) Income Margin non-GAAP | 14.1% | Three Months Ended June 30, 2026 | — |
| Non-GAAP Operating Income non-GAAP | $202.7M | First Half 2026 | — |
| Non-GAAP Operating Income Margin non-GAAP | 12.2% | First Half 2026 | — |
| Non-GAAP Organic Revenue year-on-year growth rate non-GAAP | 2.8% | Three Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BRKRP
this stock
Bruker Corp
|
$9.42B | +21.9% | +7.3% | — | — |
|
ABT
Abbott Laboratories
|
$179.99B | -17.7% | +5.7% | 33.4 | 1.0% |
|
MDT
Medtronic plc
|
$121.25B | -2.2% | +8.4% | 23.4 | 10.9% |
|
SYK
Stryker Corp
|
$115.17B | -14.2% | +11.2% | 31.1 | 1.5% |
|
BSX
Boston Scientific Corp
|
$65.30B | -52.7% | +12.5% | 18.2 | 2.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Sep 22, 2026
- This year
- 23
Bruker Corp reported lighter-than-expected second-quarter revenue, greater than 100% China order growth and greater than 50% semi-metrology order growth, while targeting 150 plus basis points of operating margin expansion in 2026.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BRKRP | +6.5% | -5.2% | +52.6% | -5.3% | +22.0% |
| SPY | +0.1% | +0.7% | +4.9% | +0.9% | +12.9% |
| vs SPY | +6.4% | -5.9% | +47.7% | -6.2% | +9.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.